Quinone compounds for treating APE1 mediated diseases

Patent metadata

Field	Value
Publication number	US-10154973-B2
Application number	US-201815868245-A
Country	US
Kind code	B2
Filing date	Jan 11, 2018
Priority date	May 26, 2011
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.

First claim

What is claimed is:

1. A compound of the formula

or a pharmaceutically acceptable salt thereof, wherein:
R is alkoxy;
X is CH═CR X ; and wherein R X is C 1 -C 10 alkyl; and
Y is NR 2 OR 2 or N(R 1 ) 2 , where each R 1 is alkyl; where each R 2 is independently selected from the group consisting of hydrogen and alkyl.

2. The compound of claim 1 , wherein R is methoxy.

3. The compound of claim 1 , wherein each R 1 is methyl or ethyl.

4. The compound of claim 1 , wherein at least one R 2 is hydrogen.

5. The compound of claim 1 , wherein at least one R 2 is alkyl.

6. The compound of claim 1 , wherein one R 2 is alkyl, and one R 2 is hydrogen.

7. The compound of claim 1 , wherein Y is NR 2 OR 2 .

8. The compound of claim 1 , wherein Y is N(R 1 ) 2 .

9. The compound of claim 1 , wherein both R 2 are methyl.

10. The compound of claim 1 , wherein R x is C 1 -C 9 alkyl.

11. The compound of claim 1 , wherein R x is C 9 alkyl.

12. The compound of claim 1 , wherein R x is n-nonyl.

13. The compound of claim 1 , wherein R x is C 1 -C 6 alkyl.

14. The compound of claim 1 , wherein R x is C 1 -C 4 alkyl.

15. The compound of claim 1 , wherein R x is C 3 -C 4 alkyl.

16. The compound of claim 1 , wherein R x is methyl.

17. A pharmaceutical composition comprising one or more compounds of claim 1 .

18. The composition of claim 17 , further comprising one or more carriers, or excipients, or a combination thereof.

19. A unit dose or unit dosage form composition comprising one or more compounds of claim 1 for treating a disease responsive to Ape1 inhibition.

Assignees

• Univ Indiana Res & Tech Corp
• Apexian Pharmaceuticals Inc

Inventors

• Kelley Mark R
• Wikel James H

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/04

  specific for metastasis · CPC title